View Older Stories View More Recent Stories

Mar 13, 2018 07:00AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
Mar 7, 2018 05:08PM Merck (MRK), Eisai Co. Enter Strategic Oncology Collaboration for LENVIMA
Mar 7, 2018 05:05PM Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Mar 1, 2018 07:10AM Merck (MRK) to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI
Mar 1, 2018 07:00AM Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
Feb 23, 2018 07:30AM Merck (MRK) Announces LYNPARZA Received Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 23, 2018 07:30AM LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer
Feb 21, 2018 06:13AM Merck (MRK) to Acquire Viralytics for $394 Million
Feb 21, 2018 04:00AM Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
Feb 15, 2018 08:45AM Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC
Feb 15, 2018 08:30AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Feb 15, 2018 06:31AM AstraZeneca (AZN), Merck (MRK) Report Orphan Drug Designation by U.S. FDA for Neurofibromatosis Type 1
Feb 15, 2018 06:30AM Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1
Feb 13, 2018 04:34PM Merck (MRK) Ends APECS Study Evaluating Verubecestat (MK-8931) for Treatment of People with Prodromal Alzheimer's Disease
Feb 13, 2018 04:30PM Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease
Feb 6, 2018 05:30PM First-of-its-Kind Study Reveals Concern about the Future of the Veterinary Profession
Feb 2, 2018 06:45AM Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results
Jan 31, 2018 07:00AM Pro Football Hall of Famer and Cancer Survivor Jim Kelly Joins Merck to Challenge America to Raise Funds for the Cancer Community
Jan 24, 2018 07:00AM Inge Thulin Elected to Merck Board of Directors
Jan 23, 2018 02:47PM Merck Announces Second-Quarter 2018 Dividend
Jan 19, 2018 06:46AM Merck (MRK) Says First-Time Data for its KEYTRUDA in Patients with Previously Treated Advanced HCC to be Presented at ASCO GI Symposium
Jan 19, 2018 06:45AM First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium
Jan 19, 2018 06:37AM Merck (MRK) and AstraZeneca (AZN) Granted Approval for LYNPARZA (Olaparib) in Japan
Jan 19, 2018 06:30AM LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer
Jan 16, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved OS and PFS as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic NSCLC
Jan 16, 2018 06:45AM Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Pati
Jan 12, 2018 12:46PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Was Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer
Jan 12, 2018 12:45PM U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer
Jan 9, 2018 06:47AM Merck (MRK) and Eisai Secure Breakthrough Therapy Designation from FDA for LENVIMA (lenvatinib mesylate) & KEYTRUDA (pembrolizumab) as Combination Therapy for Advanced RCC
Jan 9, 2018 06:45AM Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Ca
Jan 8, 2018 06:46AM Merck's (MRK) KEYTRUDA Significantly Improved RFS Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
Jan 8, 2018 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054
Jan 8, 2018 06:31AM Merck (MRK) Says FDA Accepted NDA for its Doravirine for Treatment of HIV-1 Infection
Jan 8, 2018 06:30AM FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
Jan 3, 2018 04:45PM Merck to Participate at the 36th Annual J.P. Morgan Healthcare Conference
Jan 3, 2018 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2
Jan 2, 2018 07:02AM Merck (MRK) Reports KEYTRUDA Approval in Japan for Use in Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery
Jan 2, 2018 07:00AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma That is Unresectable with Radical Surgery Who Have Progressed Following Cancer Che
Dec 22, 2017 07:02AM Merck (MRK) and Pfizer (PFE) Announce FDA Approval of SGLT2 Inhibitor STEGLATRO and Fixed-Dose Combination STEGLUJAN for Adults with Type 2 Diabetes
Dec 22, 2017 07:00AM FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes
Dec 21, 2017 01:10PM Merck (MRK) and Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Avelumab, INLYTA Combo in Advanced Renal Cell Carcinom
Dec 21, 2017 01:07PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 21, 2017 01:00PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Dec 14, 2017 04:47PM Merck (MRK) Provides Update on Phase 3 Study of KEYTRUDA in Previously Treated Patients with GEJ
Dec 14, 2017 04:45PM Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
Dec 11, 2017 06:31AM Merck (MRK) Announces FDA Accepts sBLA, Assigns Priority Review to its KEYTRUDA for Treatment of Relapsed or Refractory PMBCL
Dec 11, 2017 06:30AM FDA Accepts Supplemental Biologics License Application (sBLA), Assigns Priority Review to Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell
Dec 6, 2017 05:04PM Merck (MRK) Announces NEJM Publishes Phase 3 Clinical Study of PREVYMIS, Its New CMV Prophylaxis Medicine
Dec 6, 2017 05:02PM New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS™ (letermovir), Merck’s New CMV Prophylaxis Medicine
Nov 30, 2017 09:00AM Merck Commemorates 30 Years of MECTIZAN® Donation Program Progress
View More Recent Stories View Older Stories